IL101635A0 - Pharmaceutical compositions containing colloidal particles of water insoluble active substances - Google Patents

Pharmaceutical compositions containing colloidal particles of water insoluble active substances

Info

Publication number
IL101635A0
IL101635A0 IL101635A IL10163592A IL101635A0 IL 101635 A0 IL101635 A0 IL 101635A0 IL 101635 A IL101635 A IL 101635A IL 10163592 A IL10163592 A IL 10163592A IL 101635 A0 IL101635 A0 IL 101635A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
active substances
water insoluble
colloidal particles
Prior art date
Application number
IL101635A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202407&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL101635(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL101635A0 publication Critical patent/IL101635A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
IL101635A 1991-04-19 1992-04-17 Pharmaceutical compositions containing colloidal particles of water insoluble active substances IL101635A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4112854 1991-04-19
DE4113016 1991-04-20
DE4113343 1991-04-24

Publications (1)

Publication Number Publication Date
IL101635A0 true IL101635A0 (en) 1992-12-30

Family

ID=27202407

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101635A IL101635A0 (en) 1991-04-19 1992-04-17 Pharmaceutical compositions containing colloidal particles of water insoluble active substances

Country Status (16)

Country Link
EP (1) EP0580690B2 (fr)
JP (1) JP3695754B2 (fr)
AT (1) AT410896B (fr)
AU (1) AU1577992A (fr)
CA (1) CA2108018C (fr)
DE (1) DE4291156T1 (fr)
ES (1) ES2069995T5 (fr)
FR (1) FR2675382B1 (fr)
GB (1) GB2269536B (fr)
IE (1) IE921230A1 (fr)
IL (1) IL101635A0 (fr)
IT (1) IT1254323B (fr)
MX (1) MX9201782A (fr)
NO (1) NO933695D0 (fr)
WO (1) WO1992018105A1 (fr)
ZA (1) ZA922834B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
WO1995013799A1 (fr) * 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation de microparticules biodegradables contenant un agent biologiquement actif
EP0810853B1 (fr) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols contenant des dispersions de nanoparticules
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
IL138765A0 (en) 1998-03-30 2001-10-31 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
DE69914742T2 (de) 1998-05-29 2004-11-25 Skyepharma Canada Inc., Verdun Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
PL201578B1 (pl) 1998-11-20 2009-04-30 Skyepharma Canada Inc Stała terapeutyczna postać dawkowania nierozpuszczalnego lub słabo rozpuszczalnego w wodzie związku
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
KR20120107533A (ko) 2005-11-28 2012-10-02 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
WO2008058755A1 (fr) 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication
BRPI0717721A2 (pt) 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EP3212212B1 (fr) 2014-10-31 2020-09-23 Monash University Formulation de poudre
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
CN114828889A (zh) 2019-12-06 2022-07-29 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1532993A (en) * 1975-03-07 1978-11-22 Beecham Group Ltd Injectable antibiotic compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1282405C (fr) * 1984-05-21 1991-04-02 Michael R. Violante Methode pour produire des particules dimensionnellement uniformes a partir des composes organiques insolubles dans l'eau
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CH673395A5 (fr) * 1987-01-30 1990-03-15 Ciba Geigy Ag
CA1323306C (fr) * 1987-03-05 1993-10-19 Mircea C. Popescu Preparation comprenant une solution lipidique et un agent pharmacologique
US4963362A (en) † 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
CH679277A5 (fr) † 1989-02-09 1992-01-31 Sandoz Ag

Also Published As

Publication number Publication date
GB9319585D0 (en) 1993-12-15
ITRM920281A0 (it) 1992-04-16
MX9201782A (es) 1992-10-01
AT410896B (de) 2003-08-25
WO1992018105A1 (fr) 1992-10-29
ITRM920281A1 (it) 1993-10-16
ATA901092A (de) 2003-01-15
GB2269536A (en) 1994-02-16
FR2675382A1 (fr) 1992-10-23
EP0580690A1 (fr) 1994-02-02
IE921230A1 (en) 1992-10-21
ES2069995T5 (es) 2000-11-16
JPH06506926A (ja) 1994-08-04
AU1577992A (en) 1992-11-17
CA2108018C (fr) 2003-04-15
JP3695754B2 (ja) 2005-09-14
IT1254323B (it) 1995-09-14
NO933695D0 (no) 1993-10-14
DE4291156T1 (de) 1994-10-20
FR2675382B1 (fr) 1995-05-12
CA2108018A1 (fr) 1992-10-20
GB2269536B (en) 1995-05-10
EP0580690B2 (fr) 2000-09-13
EP0580690B1 (fr) 1995-03-15
ES2069995T3 (es) 1995-05-16
ZA922834B (en) 1993-10-18

Similar Documents

Publication Publication Date Title
IL101635A0 (en) Pharmaceutical compositions containing colloidal particles of water insoluble active substances
IL113818A0 (en) Pharmaceutical active cns compounds and pharmaceutical compositions containing them
IL105220A0 (en) Cyclohexanylidene compounds and pharmaceutical compositions containing them
IL107771A0 (en) Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
IL105218A0 (en) Hexanones and pharmaceutical compositions containing them
IL105223A0 (en) Cyclohexane-ylidenes and pharmaceutical compositions containing them
IL104824A0 (en) Heterobicyclic compounds and pharmaceutical compositions containing them
HK33294A (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
IL117237A (en) Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
IL90067A0 (en) 1alpha-hydroxyvitamin-d compounds and pharmaceutical compositions containing them
DE3473827D1 (en) Highly active collagenolytic preparation and pharmaceutical compositions containing it
NZ244766A (en) Bi-aromatic compounds and pharmaceutical compositions
HUT75089A (en) Compositions containing hyaluronic acid or it's derivatives and pharmaceutical active agent
IL108019A0 (en) Hydroxyiminoalkylindole-carboxylic acid derivatives their preparation and pharmaceutical compositions containing them
GB9116472D0 (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
IL68421A0 (en) Pharmaceutical compositions containing oxicam and their preparation
IL87746A0 (en) Pharmaceutical compositions containing pharmacologically active compounds and water soluble monoesters as solubilisers therefor
IL106098A0 (en) Heteroarylnaphthalenes and pharmaceutical compositions containing them
IL92138A0 (en) Pharmaceutical compositions containing piroxicam and their preparation
IL108073A0 (en) Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them
IL97122A0 (en) Aromatase-inhibiting androstendiones and pharmaceutical compositions containing them
IL105135A (en) Carbapenems their preparation their use and pharmaceutical compositions containing them
HU9303633D0 (en) Controlled-release pharmaceutical compositions containing nicergoline
IL104417A0 (en) Substituted dihydroindene and-acenaphthene derivatives and pharmaceutical compositions containing them
GB2264941B (en) Preparation of granular compositions